A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–120
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Subjects must be willing and able to give signed and dated written informed consent
Patients with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control
Subjects should have been taking the same daily dose of metformin ≥ 1500 mg
Fasting Plasma Glucose ≤ 270 mg/dL (≤15 mmol/L)
Males and females, aged ≥18 years old at time of screening visit
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test
WOCBP and males must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug
You may not be if
Clinical diagnosis of type I diabetes
History of diabetic ketoacidosis
Cardiovascular/vascular diseases within 3 months of the enrollment
Renal disease
Hepatic diseases
History of, or currently, acute or chronic pancreatitis
Hematological and oncological disease/conditions
Patients who have contraindications to therapy being studied
Patients on weight loss program(s)
Replacement or chronic systemic corticosteroid therapy
Clareo Health | A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
